×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
NASDAQ:RNA

Avidity Biosciences Price Target, Predictions & Analyst Ratings

$14.31
+0.16 (+1.13%)
(As of 06/29/2022 03:59 PM ET)
Add
Compare
Today's Range
$13.82
$14.69
50-Day Range
$11.18
$18.01
52-Week Range
$10.89
$29.25
Volume
28,960 shs
Average Volume
302,756 shs
Market Capitalization
$712.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.50

Avidity Biosciences (NASDAQ:RNA) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$49.50
245.91% Upside
High Price Target$59.00
Average Price Target$49.50
Low Price Target$36.00
TypeCurrent
6/29/21 to 6/29/22
1 Month Ago
5/30/21 to 5/30/22
3 Months Ago
3/31/21 to 3/31/22
1 Year Ago
6/29/20 to 6/29/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$49.50$49.60$49.60$45.00
Predicted Upside245.91% Upside119.41% Upside119.41% Upside75.54% Upside
Get Avidity Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.


RNA Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RNA Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Avidity Biosciences Stock vs. The Competition

TypeAvidity BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.71
2.51
Consensus RatingBuyBuyBuy
Predicted Upside249.82% Upside438.03% Upside31.98% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
112
61.54%
Underperform Votes
70
38.46%
Avg. Outperform Votes
170
67.19%
Avg. Underperform Votes
83
32.81%
Avg. Outperform Votes
840
69.14%
Avg. Underperform Votes
375
30.86%

Historical Avidity Biosciences Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/10/2021Wells Fargo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Yanan Zhu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$59.00+142.10%
12/10/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$36.00 ➝ $53.00+120.56%
9/7/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$50.00+159.88%
8/10/2021Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$37.00 ➝ $36.00+86.53%
6/17/2021Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+91.64%
7/7/2020Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
(Data available from 6/29/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Avidity Biosciences Price Target - Frequently Asked Questions

What is Avidity Biosciences's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Avidity Biosciences stock is Buy based on the current 4 buy ratings for RNA. The average twelve-month price prediction for Avidity Biosciences is $49.50 with a high price target of $59.00 and a low price target of $36.00. Learn more on RNA's analyst rating history.

Do Wall Street analysts like Avidity Biosciences more than its competitors?

Analysts like Avidity Biosciences stock more than the stock of other Medical companies. The consensus rating score for Avidity Biosciences is 3.00 while the average consensus rating score for medical companies is 2.71. Learn more on how RNA compares to other companies.

Do MarketBeat users like Avidity Biosciences more than its competitors?

MarketBeat users like Avidity Biosciences stock less than the stock of other Medical companies. 61.54% of MarketBeat users gave Avidity Biosciences an outperform vote while medical companies recieve an average of 66.93% outperform votes by MarketBeat users.

Does Avidity Biosciences's stock price have much upside?

According to analysts, Avidity Biosciences's stock has a predicted upside of 127.74% based on their 12-month price targets.

This page (NASDAQ:RNA) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.